Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 6/20 | 0.41 |
| ▸ | NAMPT | P43490 | 7/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199648 | 0.90 | HTR2C (0.44) | MMP13EPHX2MMP2ADAM17 | |
| SCHEMBL7208848 | 0.89 | CHRNB2 (0.44) | MMP13NAMPTMMP1EPHX2MMP2 | |
| SCHEMBL7204519 | 0.88 | MMP13 (0.43) | MMP13MMP1EPHX2MMP2ADAM17 | |
| SCHEMBL7202573 | 0.88 | MMP13 (0.43) | MMP13NAMPTMMP1EPHX2MMP2 | |
| SCHEMBL7200991 | 0.88 | MMP13 (0.43) | MMP13MMP1EPHX2MMP2ADAM17 | |
| SCHEMBL7201546 | 0.88 | SMN1; SMN2 (0.48) | MMP13MMP1EPHX2MMP2MMP14 | |
| SCHEMBL7207005 | 0.85 | MMP13 (0.42) | MMP13NAMPTMMP1MMP2MMP14 | |
| SCHEMBL7205659 | 0.85 | TP53 (0.41) | MMP13NAMPTMMP1MMP2ADAM17 | |
| SCHEMBL7202351 | 0.84 | ADAM17 (0.45) | MMP13ADAM17 | |
| SCHEMBL7200602 | 0.83 | EPHX2 (0.41) | MMP13MMP1EPHX2MMP2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | MMP13 4/4885NAMPT 4299/4885MMP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.